• Education
  • |
  • Points
  • Get the app
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The MIMS logo.
  • Home
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The MIMS logo.
Home Find Drugs Pill Identifier Find Drug Company Diseases Medical News & Updates
Other Services
MIMS Education MIMS Points Download App
Country
  • a globesingapore
  • a globehong kong
  • a globeindonesia
  • a globethailand
  • a globephilippines
  • a globevietnam
  • a globeindia
  • a globeaustralia
  • a globekorea
  • a globenew zealand
The MIMS logo.
  1. Home icon
  2. Medical News & Updates
  3. List of Conferences
    • Medical News & Updates
    • List of Conferences
  4. Advances in Medicine (AIM) 2026
Advances in Medicine (AIM) 2026

Advances in Medicine (AIM) 2026

Hong Kong 30 May 2026 - 31 May 2026

Imaging helps refine diagnosis and management in PsA

Imaging helps refine diagnosis and management in PsA

30 Jun 2026 byElaine Tan
Elaine Tan

Imaging complements clinical judgement in psoriatic arthritis (PsA) diagnosis and management, helping guide treatment to achieve remission or minimize disease progression, according to Professor Mikkel Østergaard of the University of Copenhagen, Denmark, who spoke at AIM 2026.

30 Jun 2026
Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease

Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease

04 Jun 2026 byKanas Chan
Kanas Chan

Early, long-term multimodal interventions are required to halt the progression of mild cognitive impairment (MCI) and Alzheimer’s disease, according to Professor Timothy Kwok of the Division of Geriatrics, Chinese University of Hong Kong (CUHK), who spoke at AIM 2026.

04 Jun 2026
Donanemab delays Alzheimer's disease progression over 3 years Donanemab delays Alzheimer's disease progression over 3 years

Donanemab delays Alzheimer's disease progression over 3 years

04 Jun 2026 byKanas Chan
Kanas Chan

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026. 

04 Jun 2026
The MIMS logo.
  • Drugs
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • MIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Editorial Advisory Board
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Points
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with MIMS
A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
MIMS Specialty release/v3.16.0_3176.1
Copyright © 2026 MIMS Pte Ltd. All rights reserved. UAT
MIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.